Step Aside Juno (JUNO): World's Richest Doctor Pulls Off Largest Biotech IPO Ever
Pfizer (PFE) CEO on the Prowl for New Acquisitions
Merck & Co. (MRK) Snaps up Israel Oncology Firm cCam Biotherapeutics for $605 Million
Mereo Launches With $119 Million, Three Drugs from Novartis AG (NVS) and a Partnership with ICON
BioPharm Executive: Why Some Drugmakers May See Their Profits Slashed
Biogen (BIIB) Chairman Reassures Investors With $3 Million Stock Buy
Deerfield Management Launches $550 Million Biotech Fund
PDL BioPharma (PDLI) to Infuse Up to $200 Million Into Troubled Ariad (ARIA)
Sanofi (SNY)'s Lixilan Hits Phase III Goal
Pfizer (PFE) Pulls Plug on OTC Lipitor After Trial Failure
Takeover Target or Potential Buyer? Analysts Speculate on Biogen (BIIB)’s Future After Big Stock Drop
Sanofi (SNY) and Regeneron (REGN) Ink $2.2 Billion Immuno-Oncology, PD-1 Inhibitor Deal
Allergan (AGN) Could Set its Sights on Another Transformative M&A Deal With Biogen (BIIB), Amgen (AMGN) or AbbVie (ABBV)
Analysts Wait With Bated Breath for Gilead (GILD) Q2 Results, Possible Acquisition News
Hikma (HIK.L) Snags Boehringer Ingelheim's U.S. Generics Biz for $2.65 Billion
Allergan (AGN) Considers Breaking Up Into Two Businesses Months After Actavis (ACT) Merger
Progenics Pharmaceuticals, Inc. (PGNX) Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma And Paraganglioma
FibroGen, Inc. (FGEN) Receives FDA Clearance to Proceed With Clinical Study of FG-3019 in Duchenne Muscular Dystrophy
See All News >
Takeover Target or Potential Buyer? Analysts Speculate on Biogen (BIIB)’s Future After Big Stock Drop
Sanofi (SNY) and Regeneron (REGN) Ink $2.2 Billion Immuno-Oncology, PD-1 Inhibitor Deal
Allergan (AGN) Could Set its Sights on Another Transformative M&A Deal With Biogen (BIIB), Amgen (AMGN) or AbbVie (ABBV)
Analysts Wait With Bated Breath for Gilead (GILD) Q2 Results, Possible Acquisition News
Allergan (AGN) Considers Breaking Up Into Two Businesses Months After Actavis (ACT) Merger
Progenics Pharmaceuticals, Inc. (PGNX) Announces Breakthrough Therapy Designation for Azedra in Pheochromocytoma And Paraganglioma
FibroGen, Inc. (FGEN) Receives FDA Clearance to Proceed With Clinical Study of FG-3019 in Duchenne Muscular Dystrophy
Mallinckrodt (MNK) Divests Contrast Media Biz to Guerbet (GBT) For $270 Million
Report Shows Gilead (GILD) Creates $3.5 Million per Employee
When Her Daughter Was Diagnosed With A Rare Disease, This Accountant Started A Biotech
Teva (TEVA) Snaps Up Allergan (AGN) Generics for $40.5 Billion, Ends Pursuit of Mylan (MYL)
Allergan (AGN) Coughs Up $560 Million Cash for Naurex
AstraZeneca PLC (AZN) Divests Yet Another Drug, This Time to Sanofi (SNY) for $300 Million
More Shakeups at Aegerion (AEGR) as CEO and COO Resign
Oncobiologics Secures $31 Million Financing
Bellerophon Therapeutics (BLPH) Heart Device Flunks Key Study
Embattled Vitae Pharma (VTAE) and Boehringer Ingelheim Relationship Takes Another Blow, Drops BACE Inhibitor Program for Alzheimer’s
Roche (RHHBY) Terminates $1 Billion Cancer Deal With Molecular Partners AG
See All News >
//-->